Stockwinners Market Radar for February 27, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:09 EST Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. The BP (BP)board announced that BP will exit its shareholding in Rosneft. BP has held a 19.75% shareholding in Rosneft since 2013. Additionally, BP chief executive officer Bernard Looney is resigning from the board of Rosneft with immediate effect. The other Rosneft director nominated by BP, former BP group chief executive Bob Dudley, is similarly resigning from the board. BP is expected to give rise to a non-cash adjusting item charge at the time of the first quarter 2022 results, representing the difference between the fair value of BP's Rosneft shareholding at 31 March 2022 and the carrying value of the asset. At the end of 2021 this carrying value stood at around $14 billion. In addition, the change is expected to result in non-cash adjusting item charge, principally arising from foreign exchange losses accumulated since 2013 that under IFRS were previously recorded directly in equity rather than the income statement. At the end of 2021 these totaled around $11 billion, and this adjustment will not impact equity. The change in accounting treatment also means that BP will no longer recognize a share in Rosneft's net income, production and reserves. BP will no longer report Rosneft as a separate segment from the first quarter 2022 results. 2. UPS (UPS) and FedEx (FDX) have said they are halting delivery service to Russia and Ukraine in light of the Russian invasion of its neighbor, Reuters reported. Both inbound and outbound services have been suspended to Ukraine, as well as deliveries to destinations in Russia, the companies said in online statements seen on Sunday. Meanwhile, Alphabet's (GOOGL) Google barred on Saturday Russia's state-owned media outlet RT and other channels from receiving money for ads on their websites, apps and YouTube videos, similar to a move by Facebook (FB) after the invasion of Ukraine, Reuters' Paresh Dave reported. Citing "extraordinary circumstances," Google's YouTube unit said it was "pausing a number of channels' ability to monetize on YouTube." These included several Russian channels affiliated with recent sanctions, such as those by the European Union. 3. As one of the world's leading tire makers, Goodyear Tire (GT) stands to benefit from the auto industry's transition to electric vehicles, Andrew Bary wrote in this week's edition of Barron's. Shares of Goodyear look appealing after being hammered following its fourth-quarter earnings report on Feb. 11, the author contended, adding that unlike the major auto makers that are being disrupted by the shift to electric vehicles, tire makers stand to benefit quickly. 4. Sony's (SONY) "Uncharted" won this weekend's box office with a $23.3M from 4,275 locations in its second outing for a domestic cume of $83.4M. The movie is based on the popular PlayStation game series and stars Tom Holland and Mark Wahlberg. 5. Evoqua Water Technologies (AQUA), Deere (DE), American Water Works (AWK), Southern Company (SO), CarMax (KMX), and Constellation Brands (STZ) saw positive mentions in this week's edition of Barron's.

16:47 EST BP to exit Rosneft shareholding, CEO to resign from Rosneft board - The BP board announced that BP will exit its shareholding in Rosneft. BP has held a 19.75% shareholding in Rosneft since 2013. Additionally, BP chief executive officer Bernard Looney is resigning from the board of Rosneft with immediate effect. The other Rosneft director nominated by BP, former BP group chief executive Bob Dudley, is similarly resigning from the board. As a result of the resignations of BP's nominated directors, BP has determined that it no longer meets the criteria set out under International Financial Reporting Standards for having "significant influence" over Rosneft. BP will therefore no longer equity account for its interest in Rosneft, treating it now as a financial asset measured at fair value. This will result in two material changes to BP's financial reporting and finances in the results for the first quarter of 2022. First, it is expected to give rise to a non-cash adjusting item charge at the time of the first quarter 2022 results, representing the difference between the fair value of BP's Rosneft shareholding at 31 March 2022 and the carrying value of the asset. At the end of 2021 this carrying value stood at around $14 billion. Second, in addition, the change is expected to result in non-cash adjusting item charge, principally arising from foreign exchange losses accumulated since 2013 that under IFRS were previously recorded directly in equity rather than the income statement. At the end of 2021 these totaled around $11 billion, and this adjustment will not impact equity. The change in accounting treatment also means that BP will no longer recognize a share in Rosneft's net income, production and reserves1. BP will no longer report Rosneft as a separate segment from the first quarter 2022 results. As a result of the accounting changes, and excluding Rosneft from base year and future periods, bp now expects to continue, as before, to deliver a 7-9% EBIDA per share CAGR between the second half of 2019/first half of 2020 through 2025 at oil prices of $50-$60 per barrel based on BP's planning assumptions; EBITDA from resilient hydrocarbons and group to be around $2 billion lower in 2025, at around $31 billion and $38 billion respectively. As bp now is exiting its interest in Rosneft, it has removed Rosneft dividend payments from its financial frame. However, BP says it remains confident in the flexibility and resilience of its financial frame, underpinned by an average 2021-2025 cash balance point of around $40 per barrel. This includes reaffirming the guidance regarding its expectations for shareholder distributions - dividends and buybacks - out to 2025 that was given with its 2021 full year results in February 2022.

15:39 EST Protalix, Chiesi Global Rare Diseases announce submission of MAA for PRX-102 - Protalix BioTherapeutics and Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., announced the submission of a Marketing Authorization Application via centralized procedure to the European Medicines Agency for pegunigalsidase alfa for the proposed treatment of adults with Fabry disease, and the subsequent validation of the MAA by the EMA.

15:33 EST Regeneron, Sanofi announce detailed results for Dupixent in patients with CSU - Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced detailed results for Dupixent in patients with chronic spontaneous urticaria who are biologic-naive. The pivotal trial showed adding Dupixent to standard-of-care antihistamines significantly reduced itch and hives at 24 weeks compared to antihistamines alone in this investigational setting. Topline results from the randomized, double-blind, placebo-controlled pivotal trial, which met primary and all key secondary endpoints at week 24, were announced in July 2021. Data presented at the 2022 AAAAI Annual Meeting showed that patients who added Dupixent to standard-of-care antihistamines nearly doubled the reduction in itch and urticaria activity compared to standard-of-care alone with continuous improvement out to 24 weeks. The trial demonstrated safety results similar to the known safety profile of Dupixent in its approved dermatology indications. For the 24-week treatment period, overall rates of adverse events were generally similar between the Dupixent and placebo groups. The most common adverse event was injection site reactions. The potential use of Dupixent in CSU is currently under clinical development, and the safety and efficacy have not been fully evaluated by any regulatory authority.